Earnings Call Summary | Cytek Biosciences(CTKB.US) Q1 2024 Earnings Conference
Earnings Call Summary | Cytek Biosciences(CTKB.US) Q1 2024 Earnings Conference
The following is a summary of the Cytek Biosciences, Inc. (CTKB) Q1 2024 Earnings Call Transcript:
以下是Cytek Biosciences, Inc.（CTKB）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Cytek reported a Q1 revenue of $44.9 million, up 21% year-over-year.
Gross profit reached $23 million, a 9% increase on the previous year's quarter, with a GAAP gross profit margin of 51%.
Operating expenses increased by 1.6% to $33.7 million due to a rise in headcount and personnel-related expenses.
Loss from operations was $10.7 million compared to a loss from operations of $12.2 million the previous year. Net loss also improved, down from $6.8 million prior to a current $6.2 million.
Cash flow from operations for Q1 2024 stood at a positive $4 million and total cash and marketable securities increased by $7.7 million in the quarter to $270.4 million.
Cytek報告稱，第一季度收入爲4,490萬美元，同比增長21％。
毛利達到2300萬美元，比上年同期增長9％，GAAP毛利率爲51％。
由於員工人數和人事相關支出的增加，運營支出增長了1.6％，達到3,370萬美元。
運營虧損爲1,070萬美元，而去年的運營虧損爲1,220萬美元。淨虧損也有所改善，從之前的680萬美元降至目前的620萬美元。
2024年第一季度的運營現金流爲正400萬美元，該季度的現金和有價證券總額增加了770萬美元，達到2.704億美元。
Business Progress:
業務進展：
Cytek expanded its global footprint with 99 organic Cytek instruments sold, for a total installed base of 2,247 instruments.
The company opened a new larger facility in Wuxi, China to increase manufacturing capacity.
There are over 8,500 users using the Cytek Cloud, a set of special panel design tools.
The company received IVDR compliance for its single-laser, 6-color TBNK panel in the EU market and China.
Cytek Biosciences has been accepted across multiple organizations and expects 2024 revenue to be between $203 million and $213 million, representing a 5% to 10% growth over 2023.
Their portfolio strengths reside in their flagship product, the Aurora, and they aim to focus on entry-to-mid level to drive product adoption.
Their Orion reagent mixer has seen increasing interest and they've had early successes in converting Guava customers to the Northern Lights platform.
A newly opened facility supports all product manufacturing, primarily instrument production and software improvement on Northern Lights has garnered positive customer feedback.
Cytek擴大了其全球足跡，售出了99臺有機Cytek儀器，總安裝量爲2,247臺儀器。
該公司在中國無錫開設了一座更大的新工廠，以提高製造能力。
有超過8,500名用戶在使用Cytek Cloud，這是一套特殊的面板設計工具。
該公司的單激光6色TBNK面板在歐盟市場和中國獲得了IVDR合規認證。
Cytek Biosciences已獲得多個組織的認可，預計2024年的收入將在2.03億美元至2.13億美元之間，比2023年增長5％至10％。
他們的產品組合優勢在於其旗艦產品Aurora，他們的目標是將重點放在入門級到中級產品上，以推動產品採用率。
他們的獵戶座試劑混合器引起了越來越多的興趣，他們在將番石榴客戶轉化爲北極光平台方面取得了早期成功。
新開業的工廠支持所有產品製造，主要是儀器生產和北極光軟件改進，獲得了客戶的積極反饋。
More details: Cytek Biosciences IR
更多詳情： Cytek 生物科學紅外線
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。